Cytokinetics Investor Relations Material
Latest events
Q4 2023
Cytokinetics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Cytokinetics Inc
Access all reports
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company’s lead drug candidate is tirasemtiv, a fast skeletal muscle activator that is the subject of FORTITUDE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis. It is also developing omecamtiv mecarbil an engineered cardiac myosin activator that is in Phase 2 development for the treatment of systolic heart failure.
Key slides for Cytokinetics Inc
Investor & Analyst Day 2023
Cytokinetics Inc
Investor & Analyst Day 2023
Cytokinetics Inc
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States